Table 3.

Subgroup analyses in terms of overall survival and disease-free survival.

Characteristics	Overall survival				Disease-free survival
	n	HR (95%CI)	P value	Heterogeneity	n	HR (95%CI)	P value	Heterogeneity
Study type
Retrospective	17	1.73(1.43,2.08)	<0.001	63.1	11	1.41(1.25,1.50)	<0.001	50.8%
Prospective	2	1.75(1.32,2.30)	<0.001	0.0%	1	1.53(1.01,2.30)	0.04	NA
Patients number
≥200	10	1.39(1.20,1.62)	<0.001	48.5%	6	1.33(1.17,1.51)	<0.001	6.6%
<200	9	2.57(1.92,3.45)	<0.001	19.2%	6	1.93(1.47,2.55)	<0.001	0.0%
NOS scores
>5	14	1.71(1.39,2.10)	<0.001	57.9%	9	1.43(1.25,1.62)	<0.001	40.0%
≤5	5	1.91(1.30,2.79)	0.001	72.7%	3	1.39(1.07,1.82)	0.015	0.0%
Ethnicity
Asian	12	1.78(1.37,2.31)	<0.001	66.2%	8	1.41(1.23,1.62)	<0.001	52.7%
Caucasian	7	1.68(1.33,2.12)	<0.001	53.7%	4	1.44(1.16,1.79)	0.001	0.0%
Criterion of sarcopenia
=1	15	1.93(1.51,2.47)	<0.001	66.4%	9	1.40(1.23,1.60)	<0.001	20.5%
>1	4	1.41(1.21,1.63)	<0.001	14.2%	3	1.50(1.16,1.95)	0.002	74.7%
Tumor type
Rectal cancer	11	2.37(1.61,3.48)	<0.001	70.8%	5	1.94(1.40,2.68)	<0.001	36.2%
Colorectal cancer	8	1.42(1.26,1.65)	<0.001	31.0%	7	1.36(1.20,2.42)	<0.001	0.0%

HR, hazard radio; NA, not applicable.